Poniard Pharmaceuticals, Inc. (PARD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Seattle, WA, アメリカ. 現CEOは Robert F. Caspari.
PARD を有する IPO日 1988-08-11, 7 名の正社員, に上場 Other OTC, 時価総額 $15.00.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
